vs
OCULAR THERAPEUTIX, INC（OCUL）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是OCULAR THERAPEUTIX, INC的1.1倍（$14.0M vs $13.3M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -488.0%，领先497.8%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -22.4%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-57.1M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -5.3%）
Ocular Therapeutix是一家专注于眼科疗法研发和商业化的生物制药企业，核心产品覆盖术后疼痛、青光眼、干眼症等急慢性眼部疾病的治疗，主要服务美国及部分全球市场的眼科医疗机构与患者。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
OCUL vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.1倍
$13.3M
营收增速更快
RVSB
高出32.8%
-22.4%
净利率更高
RVSB
高出497.8%
-488.0%
自由现金流更多
RVSB
多$56.4M
$-57.1M
两年增速更快
RVSB
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $13.3M | $14.0M |
| 净利润 | $-64.7M | $1.4M |
| 毛利率 | 88.0% | — |
| 营业利润率 | -526.5% | 12.4% |
| 净利率 | -488.0% | 9.8% |
| 营收同比 | -22.4% | 10.4% |
| 净利润同比 | -33.6% | 11.8% |
| 每股收益（稀释后） | $-0.27 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OCULRVSB
| Q4 25 | $13.3M | $14.0M | ||
| Q3 25 | $14.5M | $13.6M | ||
| Q2 25 | $13.5M | $13.3M | ||
| Q1 25 | $10.7M | $12.9M | ||
| Q4 24 | $17.1M | $12.7M | ||
| Q3 24 | $15.4M | $12.8M | ||
| Q2 24 | $16.4M | $12.2M | ||
| Q1 24 | $14.8M | $9.0M |
净利润OCULRVSB
| Q4 25 | $-64.7M | $1.4M | ||
| Q3 25 | $-69.4M | $1.1M | ||
| Q2 25 | $-67.8M | $1.2M | ||
| Q1 25 | $-64.1M | $1.1M | ||
| Q4 24 | $-48.4M | $1.2M | ||
| Q3 24 | $-36.5M | $1.6M | ||
| Q2 24 | $-43.8M | $966.0K | ||
| Q1 24 | $-64.8M | $-3.0M |
毛利率OCULRVSB
| Q4 25 | 88.0% | — | ||
| Q3 25 | 87.8% | — | ||
| Q2 25 | 85.6% | — | ||
| Q1 25 | 88.2% | — | ||
| Q4 24 | 92.8% | — | ||
| Q3 24 | 89.9% | — | ||
| Q2 24 | 90.8% | — | ||
| Q1 24 | 91.0% | — |
营业利润率OCULRVSB
| Q4 25 | -526.5% | 12.4% | ||
| Q3 25 | -472.3% | 10.2% | ||
| Q2 25 | -502.6% | 11.7% | ||
| Q1 25 | -597.5% | 11.3% | ||
| Q4 24 | -296.1% | 12.4% | ||
| Q3 24 | -298.2% | 15.5% | ||
| Q2 24 | -265.1% | 10.0% | ||
| Q1 24 | -214.0% | -47.5% |
净利率OCULRVSB
| Q4 25 | -488.0% | 9.8% | ||
| Q3 25 | -477.3% | 8.1% | ||
| Q2 25 | -503.9% | 9.2% | ||
| Q1 25 | -598.7% | 8.9% | ||
| Q4 24 | -283.3% | 9.7% | ||
| Q3 24 | -236.6% | 12.2% | ||
| Q2 24 | -266.3% | 7.9% | ||
| Q1 24 | -438.9% | -34.7% |
每股收益（稀释后）OCULRVSB
| Q4 25 | $-0.27 | $0.07 | ||
| Q3 25 | $-0.38 | $0.05 | ||
| Q2 25 | $-0.39 | $0.06 | ||
| Q1 25 | $-0.38 | $0.05 | ||
| Q4 24 | $-0.25 | $0.06 | ||
| Q3 24 | $-0.22 | $0.07 | ||
| Q2 24 | $-0.26 | $0.05 | ||
| Q1 24 | $-0.49 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $737.1M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $654.3M | $164.2M |
| 总资产 | $808.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OCULRVSB
| Q4 25 | $737.1M | $28.6M | ||
| Q3 25 | $344.8M | $32.8M | ||
| Q2 25 | $391.1M | $34.2M | ||
| Q1 25 | $349.7M | $29.4M | ||
| Q4 24 | $392.1M | $25.3M | ||
| Q3 24 | $427.2M | $31.0M | ||
| Q2 24 | $459.7M | $27.8M | ||
| Q1 24 | $482.9M | $23.6M |
股东权益OCULRVSB
| Q4 25 | $654.3M | $164.2M | ||
| Q3 25 | $258.2M | $163.5M | ||
| Q2 25 | $305.9M | $162.0M | ||
| Q1 25 | $265.9M | $160.0M | ||
| Q4 24 | $315.3M | $158.3M | ||
| Q3 24 | $352.0M | $160.8M | ||
| Q2 24 | $377.7M | $155.9M | ||
| Q1 24 | $408.0M | $155.6M |
总资产OCULRVSB
| Q4 25 | $808.1M | $1.5B | ||
| Q3 25 | $410.9M | $1.5B | ||
| Q2 25 | $451.3M | $1.5B | ||
| Q1 25 | $405.9M | $1.5B | ||
| Q4 24 | $457.9M | $1.5B | ||
| Q3 24 | $490.4M | $1.5B | ||
| Q2 24 | $517.1M | $1.5B | ||
| Q1 24 | $538.9M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-54.2M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-57.1M | $-736.0K |
| 自由现金流率自由现金流/营收 | -430.9% | -5.2% |
| 资本支出强度资本支出/营收 | 21.4% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-216.9M | $20.4M |
8季度趋势，按日历期对齐
经营现金流OCULRVSB
| Q4 25 | $-54.2M | $-506.0K | ||
| Q3 25 | $-50.7M | $16.8M | ||
| Q2 25 | $-55.2M | $-697.0K | ||
| Q1 25 | $-44.7M | $8.3M | ||
| Q4 24 | $-39.4M | $2.2M | ||
| Q3 24 | $-36.6M | $764.0K | ||
| Q2 24 | $-24.8M | $5.4M | ||
| Q1 24 | $-33.9M | $12.8M |
自由现金流OCULRVSB
| Q4 25 | $-57.1M | $-736.0K | ||
| Q3 25 | $-56.7M | $16.4M | ||
| Q2 25 | $-56.5M | $-773.0K | ||
| Q1 25 | $-46.6M | $5.6M | ||
| Q4 24 | $-39.6M | $1.9M | ||
| Q3 24 | $-36.6M | $-1.4M | ||
| Q2 24 | $-25.5M | $5.3M | ||
| Q1 24 | $-34.1M | $7.1M |
自由现金流率OCULRVSB
| Q4 25 | -430.9% | -5.2% | ||
| Q3 25 | -390.0% | 120.1% | ||
| Q2 25 | -419.7% | -5.8% | ||
| Q1 25 | -435.6% | 43.1% | ||
| Q4 24 | -232.0% | 15.0% | ||
| Q3 24 | -237.6% | -11.3% | ||
| Q2 24 | -155.4% | 43.7% | ||
| Q1 24 | -231.1% | 79.0% |
资本支出强度OCULRVSB
| Q4 25 | 21.4% | 1.6% | ||
| Q3 25 | 41.2% | 2.9% | ||
| Q2 25 | 9.3% | 0.6% | ||
| Q1 25 | 18.1% | 21.0% | ||
| Q4 24 | 1.2% | 2.4% | ||
| Q3 24 | 0.6% | 17.3% | ||
| Q2 24 | 4.5% | 0.9% | ||
| Q1 24 | 1.7% | 62.0% |
现金转化率OCULRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
